1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The relationship between health-related quality of life (HRQoL) and clinical outcomes in patients with advanced renal cell carcinoma (aRCC) in CheckMate (CM) 214
    Meeting Abstract

    Cella, D.; Hamilton, M.; Blum, S. I.; Ivanescu, C.; Williams, A.; Ejzykowicz, F.; Motzer, R. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Prognostic value of the lung immune prognostic index in patients with untreated advanced renal cell carcinoma (aRCC) receiving nivolumab plus ipilimumab (N+I) or sunitinib (SUN) in the CheckMate 214 trial
    Meeting Abstract

    Carril-Ajuria, L.; Motzer, R. J.; Tannir, N. M.; McDermott, D. F.; Hammers, H. J.; Plimack, E. R.; Donskov, F.; Rini, B. I.; Jiang, R.; Lee, C. W.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib, cabozantinib and nivolumab, and as monotherapy in patients with advanced or metastatic clear cell renal cell carcinoma (NCT04300140)
    Meeting Abstract

    Beckermann, K.; Shah, N. J.; Vogelzang, N. J.; Mao, S. S.; Ornstein, M. C.; Hammers, H. J.; Gao, X.; McDermott, D. F.; Haas, N. B.; Yan, H. X.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Genomic alterations and evolution in patients with prostate cancer with histologic evidence of neuroendocrine differentiation
    Meeting Abstract

    Barnett, E.; Carbone, E.; Keegan, N. M.; Vasselman, S. E.; Nweji, B.; Zaidi, S.; Scher, H. I.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint inhibitor, as monotherapy in patients (pts) with advanced renal cell carcinoma (RCC): Preliminary results from an FTIH trial
    Meeting Abstract

    Albiges, L.; Rodriguez, L. M.; Kim, S. W.; Im, S. A.; Carcereny, E.; Rha, S. Y.; Tran, B.; Oliveira, J.; Maroto-Rey, P.; Su, W. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL), pain and safety outcomes in the phase 3 VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Herrmann, K.; Krause, B. J.; Rahbar, K.; Chi, K. N.; Morris, M. J.; Sartor, O.; Tagawa, S. T.; Kendi, A. T.; Vogelzang, N.; Calais, J.; more...
    European Journal of Nuclear Medicine and Molecular Imaging (2022)

    Fulltext@MSK | Save
  • Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) - Phase 2 study of MLN0128 (TAK-228) in patients with tumors with TSC1 or TSC2 mutations: Sub-protocol EAY131-M
    Meeting Abstract

    Hays, J.; Song, Z.; Paik, P.; Iyer, G.; Mitchell, E.; Wright, J.; Doyle, L.; Gray, R.; Wang, V.; McShane, L.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)
    Meeting Abstract

    Zebic, D.; Stockler, M. R.; Martin, A.; Pashankar, F.; Tran, B.; Mazhar, D.; Huddart, R.; Wheater, M.; Walpole, E.; Dunwoodie, E.; more...
    Asia-Pacific Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC) in the CLEAR study
    Meeting Abstract

    Porta, C. G.; Eto, M.; Motzer, R. J.; De Giorgi, U.; Buchler, T.; Basappa, N. S.; Vidal, M. J.; Tjulandin, S.; Park, S. H.; Melichar, B.; more...
    Asia-Pacific Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Characterization and management of adverse reactions (ARs) in patients with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (CLEAR study)
    Meeting Abstract

    Motzer, R.; George, S.; Merchan, J. R.; Hutson, T. E.; Song, X.; Perini, R. F.; Xie, R.; Bapat, U.; Ebaid, B.; Puente, J.
    Asia-Pacific Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save